# AstraZeneca’s AZD1222 vaccine highly effective in preventing COVID-19

- Link: https://www.directorstalkinterviews.com/astrazenecas-azd1222-vaccine-highly-effective-in-preventing-covid-19/412940562
- Published: 2020-11-23T07:17:51+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has announced that positive high-level results from an interim analysis of clinical
trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in
preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases
of the disease were reported in participants receiving the vaccine. There were a
total of 131 COVID-19 cases in the interim analysis.

One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given
as a half dose, followed by a full dose at least one month apart, and another dosing
regimen (n=8,895) showed 62% efficacy when given as two full doses at least one 
month apart. The combined analysis from both dosing regimens (n=11,636) resulted
in an average efficacy of 70%. All results were statistically significant (p<=0.0001).
More data will continue to accumulate and additional analysis will be conducted,
refining the efficacy reading and establishing the duration of protection.

An independent Data Safety Monitoring Board determined that the analysis met its
primary endpoint showing protection from COVID-19 occurring 14 days or more after
receiving two doses of the vaccine. No serious safety events related to the vaccine
have been confirmed. AZD1222 was well tolerated across both dosing regimens.

AstraZeneca will now immediately prepare regulatory submission of the data to authorities
around the world that have a framework in place for conditional or early approval.
The Company will seek an Emergency Use Listing from the World Health Organization
for an accelerated pathway to vaccine availability in low-income countries. In parallel,
the full analysis of the interim results is being submitted for publication in a
peer-reviewed journal.

> **Professor Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial at 
> Oxford, said:** “These  findings  show  that  we  have  an  effective  vaccine
> that  will  save  many  lives. Excitingly, we’ve found that one of our dosing 
> regimens may be around 90% effective and if this dosing regime is used, more people
> could be vaccinated with planned vaccine supply. Today’s announcement is only 
> possible thanks  to  the  many  volunteers  in  our  trial,  and  the  hard  working
> and  talented  team  of  researchers based around the world.”

> **Pascal Soriot, Chief Executive Officer, said:** “Today marks an important milestone
> in our fight against the pandemic. This vaccine’s efficacy and safety confirm 
> that it will be highly effective against COVID-19 and will have an immediate impact
> on this public health emergency. Furthermore, the vaccine’s simple supply chain
> and our no-profit pledge and commitment to broad, equitable and timely access 
> means it will be affordable and globally available, supplying hundreds of millions
> of doses on approval.”

The pooled analysis included data from the COV002 Phase II/III trial in the UK and
COV003 Phase III trial in Brazil. Over 23,000 participants are being assessed following
two doses of either a half-dose/full-dose regimen or a regimen of two full doses
of AZD1222 or a comparator, meningococcal conjugate vaccine called MenACWY or saline.
The global trials are evaluating participants aged 18 years or over from diverse
racial and geographic groups who are healthy or have stable underlying medical conditions.

Clinical trials are also being conducted in the US, Japan, Russia, South Africa,
Kenya and Latin America with planned trials in other European and Asian countries.
In total, the Company expects to enrol up to 60,000 participants globally.

The Company is making rapid progress in manufacturing with a capacity of up to 3
billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval.
The vaccine can be stored, transported and handled at normal refrigerated conditions(
2-8 degrees Celsius/ 36-46 degrees Fahrenheit) for at least six months and administered
within existing healthcare settings.

AstraZeneca continues to engage with governments, multilateral organisations and
collaborators around the world to ensure broad and equitable access to the vaccine
at no profit for the duration of the pandemic.

**AZD1222AZD1222 was co-invented by the University of Oxford and its spin-out company,
Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened
version of a common cold virus (adenovirus) that causes infections in chimpanzees
and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination,
the surface spike protein is produced, priming the immune system to attack the SARS-
CoV-2 virus if it later infects the body.

Share on:
